These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38739755)

  • 1. Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries.
    Shah NS; Kityo C; Hughes MD; McCarthy C; Wallis C; Hosseinipour M; Langat D; Nyirenda M; Rassool M; Dawson R; Joseph Y; Some F; Mngqbisa R; Mukwekwerere PG; Woolley E; Godfrey C; Manabe YC; Mellors JW; Flexner C; Maartens G;
    Clin Infect Dis; 2024 May; ():. PubMed ID: 38739755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
    Griesel R; Zhao Y; Simmons B; Omar Z; Wiesner L; Keene CM; Hill AM; Meintjes G; Maartens G
    Lancet HIV; 2023 Jul; 10(7):e433-e441. PubMed ID: 37230101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results.
    McCluskey SM; Muyindike WR; Nanfuka V; Omoding D; Komukama N; Barigye IT; Kansiime L; Tumusiime J; Aung TN; Stuckwisch A; Hedt-Gauthier B; Marconi VC; Moosa MS; Pillay D; Giandhari J; Lessells R; Gupta RK; Siedner MJ
    J Infect Dis; 2024 Sep; 230(3):e622-e630. PubMed ID: 38748986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
    Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.
    Kouamou V; Washaya T; Ndhlovu CE; Manasa J
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.
    Asare K; Lewis L; van der Molen J; Sookrajh Y; Khubone T; Moodley P; Lessells RJ; Naidoo K; Sosibo P; Garrett N; Dorward J
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad583. PubMed ID: 38045558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D
    D2EFT Study Group
    Lancet HIV; 2024 Jul; 11(7):e436-e448. PubMed ID: 38788744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.
    Romo ML; Brazier E; Mahambou-Nsondé D; De Waal R; Sekaggya-Wiltshire C; Chimbetete C; Muyindike WR; Murenzi G; Kunzekwenyika C; Tiendrebeogo T; Muhairwe JA; Lelo P; Dzudie A; Twizere C; Rafael I; Ezechi OC; Diero L; Yotebieng M; Fenner L; Wools-Kaloustian KK; Shah NS; Nash D;
    J Int AIDS Soc; 2022 Jul; 25(7):e25961. PubMed ID: 35848120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
    Keene CM; Griesel R; Zhao Y; Gcwabe Z; Sayed K; Hill A; Cassidy T; Ngwenya O; Jackson A; van Zyl G; Schutz C; Goliath R; Flowers T; Goemaere E; Wiesner L; Simmons B; Maartens G; Meintjes G
    AIDS; 2021 Jul; 35(9):1423-1432. PubMed ID: 33973876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
    Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
    HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
    Dorward J; Sookrajh Y; Khubone T; van der Molen J; Govender R; Phakathi S; Lewis L; Bottomley C; Maraj M; Lessells RJ; Naidoo K; Butler CC; Van Heerden R; Garrett N
    Lancet HIV; 2023 May; 10(5):e284-e294. PubMed ID: 37001536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine.
    Chaisson LH; Semitala FC; Nangobi F; Steinmetz S; Marquez C; Armstrong DT; Opira B; Kamya MR; Phillips PPJ; Dowdy DW; Yoon C
    AIDS; 2023 Jun; 37(7):1097-1101. PubMed ID: 36779500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.
    Luwaya EL; Mwape L; Bwalya K; Siakabanze C; Hamooya BM; Masenga SK
    PLoS One; 2024; 19(9):e0308869. PubMed ID: 39241081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
    Zhao Y; Griesel R; Omar Z; Simmons B; Hill A; van Zyl G; Keene C; Maartens G; Meintjes G
    Clin Infect Dis; 2023 May; 76(10):1832-1840. PubMed ID: 36645792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
    Kouamou V; Machekano R; Mapangisana T; Maposhere C; Munyati S; Mutsvangwa J; Shamu T; McCarty K; Katzenstein D; Manasa J
    AIDS Res Hum Retroviruses; 2022 Oct; 38(10):774-778. PubMed ID: 35959737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S; Ayalew K; Maimela G; Briggs-Hagen M; van Wyk-Heath M; Mthethwa S; Shai S; Mngomezulu NN; Tlhowe L; Achere-Darko J; Bedford J; Martin CE; Fairlie L; Imrie J
    HIV Med; 2024 Jul; 25(7):826-839. PubMed ID: 38520085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART.
    Zhao Y; Voget J; Singini I; Omar Z; Mudaly V; Boulle A; Maartens G; Meintjes G
    South Afr J HIV Med; 2024; 25(1):1567. PubMed ID: 38725705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Tolerability of Tenofovir/Lamivudine/Dolutegravir among Antiretroviral Therapy Naive Human Immunodeficiency Virus Infected Patients of a Tertiary Care Center in Eastern India.
    Sengupta D; Ghosh S; Pain S; Chatterjee N
    J Assoc Physicians India; 2023 Sep; 71(9):72-74. PubMed ID: 38700305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
    Semengue ENJ; Fokam J; Etame NK; Molimbou E; Chenwi CA; Takou D; Mossiang L; Meledie AP; Yagai B; Nka AD; Dambaya B; Teto G; Ka'e AC; Beloumou GA; Djupsa Ndjeyep SC; Abba A; Kengni AMN; Tommo Tchouaket MC; Bouba NP; Billong SC; Sosso SM; Colizzi V; Perno CF; Kouanfack C; Zoung-Kanyi Bissek AC; Eben-Moussi E; Santoro MM; Ceccherini-Silberstein F; Ndjolo A
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.